|

Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection

RECRUITINGSponsored by Nanjing IASO Biotechnology Co., Ltd.
Actively Recruiting
SponsorNanjing IASO Biotechnology Co., Ltd.
Started2024-12-15
Est. completion2040-12
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07028970

Summary

This is a multicenter, open-label, single-arm, long-term follow-up clinical study. All patients who have received Equecabtagene Autoleucel Injection treatment will be enrolled.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

\- 1.Received Equecabtagene Autoleucel Injection treatment; 2.For those who participated in pre-marketing clinical studies or post-marketing real-world studies, must have completed or withdrawn from the original study; 3.Voluntary signing of an informed consent form approved by the ethics committee.

Exclusion Criteria:

* 1\. Receipt of another lentiviral vector-based cell or gene therapy (either commercialized product or investigational product in a clinical tiral) between the infution of Equecabtagene Autoleucel Injection and the signing informed consent.

Conditions2

CancerMultiple Myeloma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.